Shree Ganesh Remedies growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr2 yr
Revenue+0.6%−6.8%
EBITDA−10.7%−8.5%
Net Income−23.1%−20.5%
EPS (adj.)−23.1%−20.5%
Total Assets+8.2%+10.2%
Total Equity+12.3%+15.6%
Free Cash Flow−22.6%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹658.00

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹845 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+0.6-6.8
EBITDA-10.7-8.5
Net Income-23.1-20.5
EPS (adj.)-23.1-20.5
Total Assets+8.2+10.2
Total Equity+12.3+15.6
Free Cash Flow-22.6—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.